

Corporate Announcement

DKSH Singapore Secures Approval of Mounjaro® (tirzepatide) KwikPen® in Singapore

DKSH Singapore is pleased to receive the approval of Mounjaro® (tirzepatide) KwikPen®, an innovative medicine with tremendous impact on millions of people living with obesity and type 2 diabetes around the world, the first and only treatment activating two incretin hormone receptors, GIP and GLP-1.

Singapore, August 29, 2025 – DKSH Singapore is pleased to secure the approval of Mounjaro® (tirzepatide) KwikPen® on June 18, 2025, which enhances blood sugar control and promote significant weight loss, addressing an unmet medical need for the growing prevalence of Type 2 diabetes and obesity in Singapore.⁽¹⁾ This pivotal approval represents a significant advancement in the treatment of metabolic diseases, with the potential to improve outcomes for patients with type 2 diabetes and obesity, in addition to supporting the nation's health efforts to combat metabolic diseases.⁽²⁾

Mounjaro® (tirzepatide) KwikPen® is a once-weekly prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise; as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes; and as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m² (obesity) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Please see the full prescribing information for Mounjaro® (tirzepatide) KwikPen®.⁽³⁾

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has demonstrated clinically meaningful weight loss in patients seen in pivotal clinical trials⁽⁴⁾⁽⁵⁾.

DKSH Singapore was granted distribution and promotion rights for Mounjaro® (tirzepatide) KwikPen® following its appointment by Eli Lilly and Company as the marketing authorization for the medicine in Singapore.

As a strategic partner of Lilly, DKSH Singapore is proud to bring this breakthrough treatment to patients. Our dedication to improving patient access to innovative healthcare solutions is in line with our purpose to enriching lives, bringing healthcare for all. As part of this partnership, DKSH is committed to ensuring that patients and healthcare professionals have access to the latest developments in diabetes and obesity management.

About DKSH

For 160 years, DKSH has been delivering growth for companies in Asia and beyond its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people's lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. DKSH Business Unit Healthcare distributes

pharmaceuticals, consumer health, over-the-counter products, and medical devices. With around 7,940 specialists, the Business Unit generated net sales of CHF 5.7 billion in 2024. www.dksh.com/hec

For further information, please contact:

DKSH Singapore Pte Ltd

Imelda Ho

Manager, Marketing & Communications

imelda.ho@dksh.com

References

1. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4428473/>
2. [Singapore's "War on Diabetes" - The Lancet Diabetes & Endocrinology](#)
3. <https://docs.dksh.com/healthcare/sg/Mounjaro-Kwikpen-PI.pdf>
4. <https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy>
5. <https://www.medscape.com/viewarticle/tirzepatide-tops-semaglutide-weight-loss-2025a1000bdq>